Table 1.

Sera from influenza‐vaccinated or influenza‐infected persons used in the study for evaluation of sensitivity and cross‐reactivity

Serum source	Age range (yrs)	S1a	S2b	For sensitivityc		For cross‐reactivityd
				pH1	H5	H2	H5	H7	H9	H13
H5N1 vaccineese	30‐59	13	13	N/A	13	13	N/A	13	13	13
A(H1N1)pdm09 infected personsf	19‐49	21	21	21	N/A	21	21	21	21	21
pH1N1 vaccineesg	26‐64	15	15	15	N/A	15	15	15	15	15
Total number of specimens	19‐64	49	49	36	13	49	36	49	49	49

^aPre‐vaccination sera (S1) from vaccine studies or acute sera (S1) from A(H1N1)pdm09 virus‐infected persons were collected from US residents.

^bPost‐vaccination sera (S2) or convalescent (S2) showed HI ≥ 40, MN ≥ 80, and fourfold or greater rise in antibody titer, all sera collected from US residents.

^cSerum sample pairs were used to determine sensitivity by fold rises in MFI and DPP values for exposed antigens.

^dSerum sample pairs were used to determine cross‐reactivity by fold rises in MFI and DPP values for unexposed antigens.

^eSera were collected from ASO3‐adjuvanted A/Indonesia/05/2005 (H5N1) vaccine study.

^fSera were collected from pH1N1‐infected persons.

^gSera were collected from split monovalent A/California/07/09 (pH1N1) vaccine study.